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Abstract
The advent of adverse outcome pathways (AOPs) has provided a new lexicon for description of mechanistic toxicology, 
and a renewed enthusiasm for exploring modes of action resulting in adverse health and environmental effects. In addition, 
AOPs have been used successfully as a framework for the design and development of non-animal approaches to toxicity 
testing. Although the value of AOPs is widely recognised, there remain challenges and opportunities associated with their 
use in practise. The purpose of this article is to consider specifically how the future trajectory of AOPs may provide a basis 
for addressing some of those challenges and opportunities.
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Introduction
Adverse outcome pathways (AOPs) are a relatively recent 
development in mammalian and environmental toxicol-
ogy. In 2012 the Organisation for Economic Cooperation 
and Development (OECD) launched a programme for the 
development of AOPs as pragmatic analytical constructs for 
the description of linked causally related events and that 
result in the manifestation of adverse health or environmen-
tal effects. They are characterised by the identification of a 
molecular initiating event (MIE) and a series of key events 
(KE) that flow from the MIE that represent mandatory steps, 
usually of increasing biological complexity, in the pathway 
to elicitation of an adverse effect (Ankley et al. 2010; Vinken 
2013; OECD 2013, 2018). One illustrative example of this 
approach is the development of an AOP for skin sensiti-
sation; perhaps one of the most complete AOPs currently 
available (OECD 2012).
One of the benefits that derive from the AOP initiative 
is a renewed focus on the importance of understanding the 
mode of action (MOA) and exploiting that understanding to 
improve hazard characterisation and risk assessment. More-
over, AOPs have been of value in driving the development 
and application of non-animal approaches to hazard and risk 
assessment (Burden et al. 2015; Jacobs et al. 2016), and 
are now also being employed in the development of defined 
approaches for in vitro OECD test guidelines.
Despite the undoubted benefits that have been afforded 
by AOPs, there are nevertheless challenges associated with 
their application, and opportunities to extend further their 
contributions to toxicological science, and protecting human 
health and the environment (Hutchinson et al. 2013; Perkins 
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et al. 2015; Oki et al. 2016; Wittwehr et al. 2017; Leist et al. 
2017; LaLone et al. 2017). Against that background, the 
purpose of this article is to consider the future trajectory 
of AOPs and how new developments might allow chal-
lenges and opportunities to be addressed, including their 
more effective use in screening and risk assessment and their 
application in a regulatory context.
The future trajectory of AOPs
Single, linear, qualitative AOPs are likely to be of limited 
use for the purposes of risk assessment. Biochemical and 
biological pathways are complex and tightly regulated in 
space and time, and that complexity needs to be reflected in 
the next generation of AOPs. Important also is that the basic 
tenet of toxicology is that the dose makes the poison and 
there is consequently a pressing need to ensure that wher-
ever possible AOPs reflect quantitative elements of path-
ways, and in particular the threshold required for a pathway 
to progress from one key event to the next. Linked with 
this is a clear need to integrate AOPs with considerations of 
exposure metrics and toxicokinetics such that they become 
tools to support risk assessment, rather than solely for hazard 
identification. In addition to assessing product safety there 
is growing interest in the utilisation of effects based tools 
(EBT) and methods to improve the risk assessment of effects 
related to the large number of substances that need to be 
evaluated. For example, under the auspices of the European 
Union (EU) Water Framework Directive, a number of EBTs, 
including those specifically designed to measure modes of 
action in surface water, are being evaluated. These EBTs are 
being considered as tools for definition of environmental 
quality standards for specific modes of action to provide 
more holistic water quality monitoring (EU 2016a, b).
The specific areas that will be considered here are, in 
no particular order of importance: (a) quantitative AOPs 
and the importance of thresholds, (b) non-linear branching 
AOPs and AOP networks, (c) right to left AOP develop-
ment/reverse engineering AOPs, (d) the need for ontologies 
to exploit existing information, and (e) from exposure to 
outcome pathways: towards a unified paradigm for AOPs.
Quantitative AOPs and the importance of thresholds
Although in principle, AOPs differ little from considera-
tions of MOA, they provide a pragmatic framework for an 
improved understanding of the mechanistic bases for MOA, 
and for describing the sequence of biological events and 
perturbations that can result in a specific type of adverse 
health effect. However, AOPs are currently described in 
purely qualitative terms—they do not currently provide 
an understanding of quantitative relationships between the 
MIE, subsequent KEs, and the ultimate adverse outcome. 
The important, and as yet unmet, requirement is that AOPs 
reflect the thresholds required for progress between KEs in 
the pathway leading to toxicity.
An illustrative example is provided by consideration of 
one of the first, and most complete, AOPs—that for skin 
sensitisation (OECD 2012; MacKay et al. 2013). It is par-
ticularly relevant for this purpose because it is known that 
chemical allergens differ by up to five orders of magni-
tude with respect to their relative skin sensitising potency 
(Kimber et al. 2011), and this quantitative understanding is 
required for risk assessment (Basketter et al. 2014).
The AOP for skin sensitisation identifies the MIE as the 
covalent reaction of a chemical with a host protein. Sub-
sequently a number of KEs are described, in the following 
order: (a) keratinocyte activation and skin inflammation, 
with associated altered gene expression, (b) activation of 
dendritic cells (DC) and the several important contributions 
they make to uptake, processing and transporting of antigen 
to lymph nodes draining the site of exposure, and (c) the 
activation and proliferation of allergen-responsive T cells in 
these lymph nodes. This signals the induction of skin sen-
sitisation. If the sensitised individual is re-exposed to the 
same allergen, at either the same or a different skin site, then 
the previously expanded population of allergen-responsive T 
cells, created during the final KE above, will mount an accel-
erated and more aggressive secondary immune response, 
resulting in cutaneous inflammation (allergic contact der-
matitis; ACD). In this example ACD is the organism-level 
adverse health effect, or adverse outcome.
It is known that the vigour of T cell proliferation induced 
in lymph nodes draining the site of exposure to a chemical 
allergen correlates with the extent of sensitisation achieved 
(Kimber et al. 2011). However, what remain uncertain are 
the quantitative relationships between the MIE and the fol-
lowing KE, and between the sequence of KEs. For instance, 
how much adduct formation is required during the MIE to 
trigger the subsequent events in the skin that are required for 
the development of sensitisation? Is there a certain minimum 
(threshold) level of DC migration to lymph nodes that is 
necessary to support sufficient T cell activation and prolif-
eration? These are not easy questions to address, but they are 
critical if the aim is to develop paradigms for assessment of 
relative skin sensitising potency without recourse to tradi-
tional animal-based methods, and will both improve hazard 
characterisation and facilitate risk assessment.
In all areas there may be some data regarding the thresh-
olds characterising key event relationships (KERs) that 
already exist, and may include information on dose–response 
relationships, and temporal concordance, between KEs. 
However, these data may simply not yet have been captured, 
or been made available in a readily accessible form. If sup-
porting evidence for KEs and KERs was suitably annotated 
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with dose and time information, then it is possible that the 
temporal and dose-concordance between KEs could be 
inferred computationally based on Bradford Hill considera-
tions (Becker et al. 2015).
Non‑linear/branching AOPs and AOP networks
The key principles for AOP development proposed by Vil-
leneuve et al. (2014) acknowledge that biological pathways, 
including those perturbed as a result of toxicity, do not oper-
ate in isolation from each other, but suggest that it is most 
pragmatic to consider AOPs as single chains of KEs, each 
arising from one MIE and leading to one adverse outcome. 
As increasing numbers of AOPs are populated in the AOP-
Wiki, common KEs involved in multiple AOPs are being 
identified. This allows information that has been curated 
for one AOP to be reused in another, avoiding duplication 
of effort. This does, however, indicate that it will become 
increasingly important to move away from viewing single 
linear AOPs in isolation, and to instead consider non-linear 
and branching AOPs within a broader context of AOP net-
works, as guidance is now acknowledging (OECD 2018). 
Combining multiple pathways, linking a single MIE with 
multiple biological outcomes, resulting in more realis-
tic AOPs will bring important benefits informing future 
research, predictive and regulatory toxicology, and the 
development of non-animal methods (Jacobs et al. 2016). 
However, it is necessary to bear in mind that the conditions 
that propagate an AOP (i.e., causality) may differ depend-
ing on the specific circumstances (for example, according to 
animal species, cell type and exposure, etc.). It is, therefore, 
important that these and other relevant conditions are clearly 
defined and accurately recorded.
As discussed later in this article (see ontologies), existing 
information and descriptions of AOPs, KEs and KERs, will 
need to be consistent to enable the developments described 
above. In this context, it is relevant that the AOP-Wiki has 
recently been upgraded to facilitate the use of a defined 
set of ontologies to define ‘event components’ as consist-
ent structured descriptions of KEs and their contexts (Ives 
et al. 2017).
Right to left AOP development/reverse engineering 
AOPs
The current paradigm of the linear AOP encourages pathway 
development from left to right—MIE to adverse outcome. 
Thus, description of an AOP normally originates with iden-
tification of a MIE and then progresses sequentially through 
a number of KEs reflecting increasing levels of biological 
organisation and complexity until an adverse health or popu-
lation effect is reached at the tissue or organism (or popula-
tion) level (Ankley et al. 2010; Vinken 2013).
Although this approach is logical in terms of a progres-
sion from the earliest pivotal interaction of a toxicant with 
a biological system to the relevant adverse outcome, it does 
require some certainty, or at least understanding, of what the 
MIE and (at least some of) the KEs are, and the relationship 
between them. However, this is not always the case, and in 
such circumstances it may be informative to consider tack-
ling construction of an AOP from the other end of the pipe-
line. That is, to work backwards from the adverse outcome 
of interest along the pathway of KEs (Perkins et al. 2011; 
Villeneuve et al. 2014).
Such an approach has been described in developing an 
AOP for chemical respiratory allergy (Kimber et al. 2014). It 
is well established that certain chemical allergens cause sen-
sitisation of the respiratory tract resulting in allergic asthma 
and rhinitis. Although something is known of the relevant 
immunological and biological events, there remains uncer-
tainty, and a lack of a scientific consensus, regarding the 
KE required for the acquisition of sensitisation. Specifically, 
there is a continuing debate about the role of IgE antibody, 
and the relative importance of other immunological effector 
mechanisms, in driving allergic sensitisation. The reverse 
engineered AOP for chemical respiratory allergy acknowl-
edged this uncertainty and attempted to identify common 
ground that could provide a basis for the design of novel 
approaches for hazard identification and characterisation.
The learning that came from this is that in certain cir-
cumstances, where data are incomplete, or where there is 
uncertainty about a key element of the pathway leading to 
an adverse health effect; there may be merit in considering 
a reverse engineering approach.
The need for ontologies to exploit existing 
information
The use of standard ontologies (that is, the formal naming 
and definition of terminology) and descriptions will enable 
more effective sharing of information contained within 
AOPs, particularly across different sectors. Good Laboratory 
Practice (GLP) animal studies may be reportable accord-
ing to SEND (the Standard for Exchange of Non-clinical 
Data) for pharmaceuticals. Also, there is OECD guidance 
on in vitro test method reporting for both guideline (OECD 
2005), and non-guideline methods (OECD 2014), and draft 
guidance for draft good cell culture practise (OECD 2017). 
However, although databases and data-sharing initiatives 
do exist, a lack of interoperable standards means there 
remain logistical and technological barriers to the optimal 
exploitation of data (Burgoon 2017; Ives et al. 2017). This 
could be addressed through greater consolidation and use of 
ontologies, and the accompanying development of improved 
bioinformatics and data mining tools; which in turn would 
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drive greater use of available data to better define KERs and 
potentially allow automated linking of AOPs.
Opportunities exist to leverage existing ontologies and 
to agree universal standards—or a common language—for 
AOPs so that knowledge can be described and captured in 
a simple, sustainable way. Capitalising on the outcomes of 
existing consortia and data-sharing initiatives, and standard-
ising ontologies used in publications will not only broaden 
the chemical space accessible from searches, but also reveal 
commonalities of underlying toxicities and biological path-
ways. Overcoming these practical and intellectual barriers 
will help to corroborate information in existing AOPs and 
also offer the prospect of more rigour in defining future 
AOPs.
Moreover, it is not just databases and data-sharing initia-
tives that hold information crucial for the effective devel-
opment of AOPs; there is a wealth of useful information 
held in the basic scientific literature. AOPs are currently 
developed through the, largely manual, curation and inte-
gration of experimental data from the published literature 
on the biological effects of exposure to various xenobiot-
ics, but computational approaches are being explored (Bell 
et al. 2016). With improved use of ontologies, integration of 
data contained within the existing scientific literature could 
potentially be automated and enhance computational inte-
gration to infer and propose AOPs, thereby accelerating their 
development.
Exposure to outcome pathways: towards a unified 
paradigm for AOPs
A key requirement for furthering the effective use of AOPs is 
a clear understanding of the potential for human or environ-
mental exposure to the chemical of interest. The application 
of AOPs to the development of risk assessments requires 
that an appreciation of the biological events and processes 
that might flow from encounter with a chemical is coupled 
with information about the conditions of exposure (includ-
ing duration, route and extent), and fate of that chemical 
(Teeguarden et al. 2016).
As discussed above, an important aspect of AOPs is 
that there is a clear understanding of requirements (includ-
ing levels of exposure in relation to target availability and 
dynamics) for the MIE to be triggered. The same is neces-
sarily true for eliciting subsequent KEs in the AOP. There 
is, therefore, a need to extrapolate quantitative information 
on the relationships between tipping points for KEs in AOPs 
(where a biological system moves from an adaptive to an 
adverse response), in order that the predictions made can be 
considered in the context of realistic levels of human or envi-
ronmental exposure. A continuing challenge will be to align 
an increasing sophistication of AOPs, and their more wide-
spread application, with dosimetry and exposure metrics. 
How best to achieve this is still the subject of debate. How-
ever, there is a growing consensus that AOPs will best serve 
toxicology if methods can be found to integrate an apprecia-
tion of dose–response relationships and toxicokinetics with 
AOPs to build the concept of ‘source to outcome pathways’ 
that seek to embrace the totality of the processes involved 
in an aggregate exposure pathway (AEP) (Teeguarden et al. 
2016; Vinken and Blaauboer 2016; Hines et al. 2018). Such 
a development will be of critical importance in consolidat-
ing AOPs as tools for risk assessment as well as hazard 
identification.
Conclusions
It is already clear that AOPs are a force for good in toxi-
cology. They have created a new lexicon for investigating 
and describing mechanisms and modes of action, they have 
proven useful for considering new targets and new para-
digms for hazard identification and characterisation, and 
they continue to provide exciting opportunities for the design 
and implementation of non-animal approaches in toxicol-
ogy and application of the 3Rs (reduction, refinement and 
replacement) principles.
Much has been achieved already, but it is timely now to 
consider the future trajectories of AOPs to ensure that their 
potential utility in toxicology is fully realised, and impor-
tantly, that they evolve into tools that will support the devel-
opment of new and improved approaches to risk assessment. 
In this short article, we have highlighted what, in the view 
of these authors, are some of the opportunities that are now 
available to create a second generation of AOPs. The areas 
identified are not exhaustive, nor are they intended to be; 
doubtless there are other improvements and modifications 
that will also bring benefits, and one purpose of this short 
article is to stimulate further discussion about how best to 
exploit fully the opportunities provided by AOPs.
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